Table 1.
Demographic information across the 3 studies. LEU-DA is levodopa equivalent units for dopamine agonists. In all locations, n is the number of subjects.
| ICB | PD | Controls | |
|---|---|---|---|
| Beads – n | 26 | 22 | 17 |
| Age | 58.9 (9.6) | 64.8 (5.3) | 58.8 (10.9) |
| Gender (n male) | 22 | 19 | 14 |
| N on agonist | 13 | 16 | |
| LEU – DA | 66.7 (91.7) | 160.7 (157.2) | |
| L-dopa | 865.4 (405.6) | 624.4 (338.5) | |
| Temporal Discounting – n | 18 | 18 | 20 |
| Age | 62.3 (7.6) | 67.7 (5.5) | 65.5 (6.0) |
| Gender (n male) | 11 | 12 | 10 |
| N on agonist | 11 | 11 | |
| LEU DA – n on DA | 248.0 (301.3) | 170.5 (159.3) | |
| L-dopa | 643.5 (254.1) | 634.2 (301.7) | |
| Novelty – n | 23 | 25 | 18 |
| Age | 55.9 (8.7) | 64.2 (8.1) | 57.9 (11.9) |
| Gender (n male) | 19 | 21 | 8 |
| N on agonist | 11 | 11 | |
| LEU – DA | 99.5 (150.6) | 181.7 (207.2) | |
| L-dopa | 684.8 (321.5) | 626.5 (331.0) |